IDEAYA Biosciences Now Covered by UBS Group

LSTA Stock  USD 2.65  0.07  2.71%   
About 55% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
UBS Group initiated coverage on shares of IDEAYA Biosciences in a report published on Thursday, Marketbeat.com reports. The firm issued a buy rating and a 50.00 price target on the stock. A number of other equities analysts have also issued reports on IDYA. Lifesci Capital raised IDEAYA Biosciences to a strong-buy

Read at thelincolnianonline.com
news
  

Lisata Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lisata Therapeutics Fundamental Analysis

We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Lisata Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Lisata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.

Peers

Lisata Therapeutics Related Equities

LIXTLixte Biotechnology   19.60   
0%
100.0%
PTIXProtagenic Therapeutics   7.69   
0%
39.0%
PULMPulmatrix   7.30   
0%
37.0%
CADLCandel Therapeutics   6.82   
0%
34.0%
BPTHBio Path   3.58   
0%
18.0%
IMNNImunon   3.24   
0%
16.0%
GLUEMonte Rosa   1.46   
0%
7.0%
XOMAOXOMA   0.12   
0%
1.0%
RZLTRezolute   1.11   
5.0%
0%
TPSTTempest Therapeutics   1.25   
6.0%
0%
ANTXAN2 Therapeutics   6.29   
32.0%
0%
MBRXMoleculin Biotech   15.07   
76.0%
0%

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
CEOs Directory
Screen CEOs from public companies around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stocks Directory
Find actively traded stocks across global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data